Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Intervention Model: Parallel Versus Comparator + Placebo
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient with at least 1-year history of migraines (with or without aura) including the following:
* Migraine attacks more than 1 year with age of onset prior to 50 years of age
* Migraine attacks, on average, last about 4 - 72 hours if untreated
* No more than 8 attacks of moderate to severe intensity per month within last 3 months
* Patient must be able to distinguish migraine attacks from tension/cluster attacks and must have consistent migraine headaches of at least 2 migraine headaches attacks of moderate to severe intensity in each of the last 3 months
* Less than 15 days of headache (migraine or non-migraine) per month in each of 3 months prior to screening
Male and female ≥ 18 years and ≤ age 65
No clinically significant abnormality identified on the medical or laboratory evaluation
You may not be if
Patient has a history of basilar migraine or hemiplegic migraine
Patient does not receive migraine relief from triptan migraine treatment
Medications that may alter the pH of the stomach (acid reducing agents), such as H-2 antagonists, Proton Pump inhibitors (PPI), antacids
History of ergotamine or triptan intake greater than/equal 10 days per month on a regular basis for greater than 3 months
History of non-narcotic analgesic intake on greater then/equal 15 days per month for greater than/equal 3 months
Clareo Health | Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine
